(ZTS) Zoetis - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98978V1035

Vaccines, Parasiticides, Diagnostics, Dermatology, Anti-Infectives

Pharmaceuticals
Market Cap in USD: 55,695m

IPO / Inception: 2013-02-01
Return 12m vs S&P 500: -34.8%

EPS (Earnings per Share)

EPS CAGR: -46.76%
EPS Trend: -16.6%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 5.45%
Rev. Trend: 92.3%

Last SUE: -0.14
Qual. Beats: 0

Dividends

Dividend Yield	1.99%
Yield on Cost 5y	1.56%
Yield CAGR 5y	18.92%
Payout Consistency	100.0%
Payout Ratio	32.8%

Risk via 5d forecast
Volatility	26.5%
Value at Risk 5%th	40.2%
Relative Tail Risk	-7.56%

Reward TTM
Sharpe Ratio	-0.84
Alpha	-34.67
CAGR/Max DD	-0.16

Character TTM
Hurst Exponent	0.800
Beta	0.618
Beta Downside	0.566

Drawdowns 3y
Max DD	40.89%
Mean DD	13.23%
Median DD	11.64%

Description: ZTS Zoetis December 03, 2025

Zoetis Inc. (NYSE: ZTS) develops, manufactures, and markets a broad portfolio of animal-health products-including medicines, vaccines, diagnostics, biodevices, genetic tests, and precision-health solutions-for livestock (cattle, swine, poultry, fish, sheep) and companion animals (dogs, cats, horses). Its offerings span parasiticides, anti-infectives, dermatology, pain-management, and point-of-care diagnostics, and it sells primarily to veterinarians, livestock producers, and pet owners. The company also partners with Blacksmith Medicines to explore novel animal-health antibiotics.

Key recent data points: • FY 2023 revenue reached $7.6 billion, with a 9 % YoY increase driven by strong growth in companion-animal vaccines and livestock pharmaceuticals. • The global animal-health market is projected to expand at a CAGR of ~5 % through 2028, underpinned by rising protein demand and higher pet-care spending. • Zoetis’s 2024 guidance anticipates a 6-7 % earnings-per-share growth, supported by its expanding precision-health platform and cost-efficiency initiatives in manufacturing.

For a deeper, data-driven look at ZTS’s valuation and risk profile, you may find ValueRay’s analyst tools helpful.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (2.65b TTM) > 0 and > 6% of Revenue (6% = 563.8m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA -1.30pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 50.82% (prev 50.04%; Δ 0.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.19 (>3.0%) and CFO 2.92b > Net Income 2.65b (YES >=105%, WARN >=100%)

Net Debt (5.19b) to EBITDA (4.05b) ratio: 1.28 <= 3.0 (WARN <= 3.5)

Current Ratio 3.64 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (443.2m) change vs 12m ago -2.27% (target <= -2.0% for YES)

Gross Margin 70.63% (prev 68.49%; Δ 2.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 63.67% (prev 63.75%; Δ -0.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.42 (EBITDA TTM 4.05b / Interest Expense TTM 231.0m) >= 6 (WARN >= 3)

Altman Z'' 7.99

(A) 0.32 = (Total Current Assets 6.58b - Total Current Liabilities 1.81b) / Total Assets 15.16b

(B) 0.90 = Retained Earnings (Balance) 13.59b / Total Assets 15.16b

warn (B) unusual magnitude: 0.90 — check mapping/units

(D) 1.31 = Book Value of Equity 12.78b / Total Liabilities 9.76b

Total Rating: 7.99 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 83.39

1. Piotroski 6.50pt

2. FCF Yield 3.68%

3. FCF Margin 23.84%

4. Debt/Equity 1.35

5. Debt/Ebitda 1.28

6. ROIC - WACC (= 17.54)%

7. RoE 53.56%

8. Rev. Trend 92.34%

9. EPS Trend -16.56%

What is the price of ZTS shares?

As of January 11, 2026, the stock is trading at USD 127.17 with a total of 3,060,992 shares traded.
Over the past week, the price has changed by +0.99%, over one month by +9.87%, over three months by -11.00% and over the past year by -21.10%.

Is ZTS a buy, sell or hold?

Zoetis has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy ZTS.

Strong Buy: 10
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ZTS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	158.2	24.4%
Analysts Target Price	158.2	24.4%
ValueRay Target Price	123.5	-2.9%

ZTS Fundamental Data Overview January 09, 2026

P/E Trailing = 21.7799
P/E Forward = 19.685
P/S = 5.9269
P/B = 10.5601
P/EG = 2.428
Beta = 0.97
Revenue TTM = 9.40b USD
EBIT TTM = 3.56b USD
EBITDA TTM = 4.05b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.35b USD (from shortTermDebt, last fiscal year)
Debt = 7.27b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.19b USD (from netDebt column, last quarter)
Enterprise Value = 60.89b USD (55.69b + Debt 7.27b - CCE 2.08b)
Interest Coverage Ratio = 15.42 (Ebit TTM 3.56b / Interest Expense TTM 231.0m)
EV/FCF = 27.18x (Enterprise Value 60.89b / FCF TTM 2.24b)
FCF Yield = 3.68% (FCF TTM 2.24b / Enterprise Value 60.89b)
FCF Margin = 23.84% (FCF TTM 2.24b / Revenue TTM 9.40b)
Net Margin = 28.21% (Net Income TTM 2.65b / Revenue TTM 9.40b)
Gross Margin = 70.63% ((Revenue TTM 9.40b - Cost of Revenue TTM 2.76b) / Revenue TTM)
Gross Margin QoQ = 71.54% (prev 72.28%)
Tobins Q-Ratio = 4.02 (Enterprise Value 60.89b / Total Assets 15.16b)
Interest Expense / Debt = 0.80% (Interest Expense 58.0m / Debt 7.27b)
Taxrate = 18.71% (166.0m / 887.0m)
NOPAT = 2.90b (EBIT 3.56b * (1 - 18.71%))
Current Ratio = 3.64 (Total Current Assets 6.58b / Total Current Liabilities 1.81b)
Debt / Equity = 1.35 (Debt 7.27b / totalStockholderEquity, last quarter 5.40b)
Debt / EBITDA = 1.28 (Net Debt 5.19b / EBITDA 4.05b)
Debt / FCF = 2.32 (Net Debt 5.19b / FCF TTM 2.24b)
Total Stockholder Equity = 4.95b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.96% (Net Income 2.65b / Total Assets 15.16b)
RoE = 53.56% (Net Income TTM 2.65b / Total Stockholder Equity 4.95b)
RoCE = 29.64% (EBIT 3.56b / Capital Employed (Equity 4.95b + L.T.Debt 7.07b))
RoIC = 24.85% (NOPAT 2.90b / Invested Capital 11.65b)
WACC = 7.32% (E(55.69b)/V(62.97b) * Re(8.19%) + D(7.27b)/V(62.97b) * Rd(0.80%) * (1-Tc(0.19)))
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.85%
[DCF Debug] Terminal Value 82.93% ; FCFF base≈2.27b ; Y1≈2.67b ; Y5≈4.08b
Fair Price DCF = 170.9 (EV 80.51b - Net Debt 5.19b = Equity 75.33b / Shares 440.7m; r=7.32% [WACC]; 5y FCF grow 18.89% → 2.90% )
EPS Correlation: -16.56 | EPS CAGR: -46.76% | SUE: -4.0 | # QB: 0
Revenue Correlation: 92.34 | Revenue CAGR: 5.45% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.58 | Chg30d=+0.007 | Revisions Net=-2 | Analysts=10
EPS next Year (2026-12-31): EPS=6.79 | Chg30d=-0.006 | Revisions Net=-4 | Growth EPS=+7.1% | Growth Revenue=+5.1%

Additional Sources for ZTS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle